Eulav Asset Management Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Eulav Asset Management

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$83.14 - $145.99 $15.4 Million - $27 Million	-185,000 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$110.08 - $142.92 $7.38 Million - $9.58 Million	-67,000 Reduced 26.59%	185,000 $21.9 Million
Q4 2021 Feb 11, 2022	SELL	$99.73 - $148.48 $3.49 Million - $5.2 Million	-35,000 Reduced 12.2%	252,000 $35.1 Million
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $7.71 Million - $10.8 Million	-78,000 Reduced 21.37%	287,000 $39.9 Million
Q2 2021 Aug 06, 2021	BUY	$65.78 - $105.02 $1.32 Million - $2.1 Million	20,000 Added 5.8%	365,000 $35.4 Million
Q1 2021 Apr 30, 2021	BUY	$64.07 - $91.75 $2.88 Million - $4.13 Million	45,000 Added 15.0%	345,000 $23.6 Million
Q4 2020 Feb 16, 2021	SELL	$65.07 - $98.24 $6.8 Million - $10.3 Million	-104,427 Reduced 25.82%	300,000 $25.7 Million
Q3 2020 Nov 05, 2020	BUY	$59.04 - $77.95 $792,730 - $1.05 Million	13,427 Added 3.43%	404,427 $26.3 Million
Q2 2020 Aug 11, 2020	BUY	$29.01 - $74.23 $609,210 - $1.56 Million	21,000 Added 5.68%	391,000 $28.6 Million
Q1 2020 Apr 27, 2020	BUY	$27.51 - $57.29 $3.03 Million - $6.3 Million	110,000 Added 42.31%	370,000 $12.6 Million
Q4 2019 Feb 13, 2020	BUY	$40.86 - $57.65 $1.63 Million - $2.31 Million	40,000 Added 18.18%	260,000 $14.2 Million
Q3 2019 Nov 12, 2019	BUY	$37.38 - $49.47 $4.11 Million - $5.44 Million	110,000 Added 100.0%	220,000 $9.18 Million
Q2 2019 Aug 05, 2019	BUY	$39.79 - $67.01 $4.38 Million - $7.37 Million	110,000 New	110,000 $4.82 Million

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

Stay updated on Eulav Asset Management with notifications on news.